Biotrofix News - Press Releases

Strategic Alliance Between Research Firms Will Combine Expertise in CNS and Vascular Disease Models with Translational, Multi-Modal Imaging

Biotrofix and Ekam Imaging announce a nonclinical CRO partnership, which will provide capabilities unique in the field of neuroscience

February, 2011 - Boston, MA — Aiming to minimize risk from preclinical development, Biotrofix and Ekam Imaging announced this month they have entered into a partnering agreement together to provide synergistic capabilities to the pharmaceutical and biotechnology industries. The goal of the partnership is to deliver high-quality, accurate and translatable data that greatly assists their sponsors by allowing them to make faster and better-informed decisions.

View Full PDF Article

Preclinical Studies Show GGF2 Promotes Functional Recovery from Stroke with Treatment Initiated Up to Seven Days After Event

Biotrofix authors are co-investigators on this study.

HAWTHORNE, N.Y., Oct 19, 2010 (BUSINESS WIRE)

Acorda Therapeutics, Inc, (NASDAQ: ACOR) today announced that data from preclinical studies show that Glial Growth Factor 2 (GGF2) promoted functional recovery following a permanent focal ischemic stroke. In a series of studies, GGF2 was administered starting up to seven days after the event to explore the neurorestorative properties of this novel growth factor. These studies were recently published online in Neuropharmacology, and the paper is scheduled to appear in a future print edition of the journal. An accompanying editorial discussed the need for new approaches in stroke intervention, and the potential role that GGF2 may play in improving function after stroke, pending further preclinical and clinical studies.

View Full PDF Article

Amorfix Life Sciences and Biotrofix Announce Detection of Aggregated Beta-Amyloid in CSF Using the A4 Alzheimer's Test

TORONTO, ON, October 21, 2010

Amorfix Life Sciences Ltd. (TSX:AMF) and Biotrofix, Inc. today announced that they have successfully detected the presence of the aggregated Beta-Amyloid (Abeta) peptide in the cerebral spinal fluid (CSF) from transgenic mice using the Amorfix A4 test. The results come from a collaborative study using the transgenic (Tg2576) mouse model of Alzheimer’s disease (AD). Following collection and analysis of CSF, plasma and brains from 3 month old transgenic and normal mice, they successfully detected the presence of the aggregated Abeta peptide in the CSF from the transgenic mice which correlated with the signal detected in the brains and plasma.

View Full PDF Article